2,3,4,5,6-pentafluoro-4'-isopropyl-1,1'-biphenyl

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,3,4,5,6-pentafluoro-4'-isopropyl-1,1'-biphenyl
• 英文别名: 2,3,4,5,6-Pentafluoro-4'-isopropyl-biphenyl；1,2,3,4,5-pentafluoro-6-(4-propan-2-ylphenyl)benzene
• 化学式: C₁₅H₁₁F₅
• 分子量: 286.244
• InChiKey: QAHXCNAHKLDSOD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  五氟苯 、 sodium 4-isopropylbenzenesulfinate 在 bis(η3-allyl-μ-chloropalladium(II)) 、 silver(l) oxide 、 2-二环己基磷-2,4,6-三异丙基联苯 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 20.0h， 以62%的产率得到2,3,4,5,6-pentafluoro-4'-isopropyl-1,1'-biphenyl
  参考文献：
  名称：

  多氟芳烃与芳基亚磺酸盐直接钯催化的脱硫C C偶联：水促进的反应

  摘要：

  描述了一种由容易获得的起始原料合成氟化联芳基化合物的新方法。该协议基于直接钯催化desulfitative交叉偶联以通过C芳基亚各种盐polyfluoroarenes的H键活化，通过水的微量加速。该方法允许的各种氟化二芳基产物的合成在中度至良好的产率，并且耐受多种官能团，包括烷基，苯基，甲氧基，氟和氯基团。

  DOI：

  10.1016/j.jfluchem.2014.06.017

文献信息

• Fluorinated biphenyls from aromatic arylations with pentafluorobenzenediazonium and related cations. Competition between arylation and azo coupling
  作者：Dmitry Kosynkin、T. Michael Bockman、Jay K. Kochi

  DOI：10.1039/a701745f

  日期：——

  High yields of the mixed perfluorinated biaryls (C6F5–Ar) are obtained by the catalytic dediazoniation of the pentafluorobenzenediazonium salt (C6F5N2+BF4–) in acetonitrile solutions containing various aromatic substrates (ArH) together with small amounts of iodide salts. Activated (electron-rich) as well as deactivated (electron-poor) arenes are successfully pentafluorophenylated by this method. The arylation is distinct from the azo coupling of the same substrates, which takes place in the absence of the iodide catalyst and yields the corresponding diazene (C6F5NN–Ar) as product. The catalytic role of iodide, and the isomeric product distributions obtained with this procedure indicate that the arylation proceeds via the pentafluorophenyl radical in a efficient homolytic chain process. Since azo coupling involves electrophilic aromatic substitution of electron-rich ArH by C6F5N2+, the two competing pathways are distinct and do not have reactive intermediates in common.

  通过催化脱重氮化反应，在含有各种芳香族底物（ArH）及少量碘化盐的乙腈溶液中，五氟苯重氮盐（C6F5N2+BF4–）能够高效生成混合全氟联苯（C6F5–Ar），产率较高。无论是活化的（电子富集的）还是去活化的（电子贫乏的）芳香族化合物，都能通过此方法成功实现五氟苯基化。这种芳基化反应与同种底物的偶氮耦合反应截然不同，后者在无碘催化剂存在下进行，产物为相应重氮烯（C6F5NN–Ar）。碘化物在催化中的作用以及由此过程获得的不同异构产物分布表明，芳基化反应是通过高效的均裂链式过程，经由五氟苯基自由基进行的。由于偶氮耦合涉及电子富集的ArH通过亲电芳香取代反应与C6F5N2+的结合，这两种竞争路径是不同的，且没有共同的反应中间体。
• Metal-Free Perfluoroarylation by Visible Light Photoredox Catalysis
  作者：Andreas U. Meyer、Tomáš Slanina、Chang-Jiang Yao、Burkhard König

  DOI：10.1021/acscatal.5b02410

  日期：2016.1.4

  Visible light and eosin Y catalyze the direct arylation of simple arenes with fluorinated aryl bromides by a photoredox process. The reaction scope is broad in fluorinated compounds and arenes and the general and simple procedure provides a metal-free alternative for the synthesis of synthetically valuable polyfluorinated biaryl structures. The mild reaction conditions allow a selective reaction with

  可见光和曙红Y通过光氧化还原过程催化简单的芳烃与氟化的芳基溴化物直接芳基化。反应范围在氟化化合物和芳烃中很宽，常规和简单的方法为合成有价值的多氟化联芳基结构提供了一种无金属的替代方法。温和的反应条件允许在不保护官能团的情况下与生物碱马钱子碱进行选择性反应，从而说明该方法可用于后期功能化。机理研究表明，曙红Y通过三乙胺通过三重态状态进行光还原，随后电子从曙红Y自由基阴离子转移到多氟溴芳烃，后者分裂成多氟芳基自由基和溴化阴离子。
• Palladium-Catalyzed Olefination and Arylation of Polyfluoroarenes Using Molecular Oxygen as the Sole Oxidant
  作者：Qiufeng Huang、Xinyu Zhang、Lin Qiu、Jiajun Wu、Hanbing Xiao、Xiaofeng Zhang、Shen Lin

  DOI：10.1002/adsc.201500632

  日期：2015.11.16

  The palladium-catalyzed cross-dehydrogenative-coupling of polyfluoroarenes with alkenes or simple arenes has been developed. The approach is characterized by using atmospheric pressure of molecular oxygen as the sole oxidant, and provides a straightforward and environmentally benign route to functionalized polyfluoroarenes.

  已经开发了钯催化的多氟芳烃与烯烃或简单芳烃的交叉脱氢偶联。该方法的特征在于使用分子氧的大气压作为唯一的氧化剂，并提供了直接且对环境无害的官能化多氟芳烃途径。
• Aryl Alkyl Sulfonamides As Therapeutic Agents For The Treatment Of Bone Conditions
  申请人：Ralston Stuart Hamilton

  公开号：US20080119555A1

  公开（公告）日：2008-05-22

  The present invention pertains to certain aryl alkyl sulfonamides and derivatives thereof which, inter alia, inhibit osteoclast survival, formation, and/or activity; and/or inhibit bone resorption, and more particularly to compounds of the formula: wherein: Ar 1 is independently C 5-20 aryl (e.g., biphenyl, phenanthryl, fluorenyl, or carbazolyl, most preferably biphenyl), and is optionally substituted; R N is independently —H, acyl, C 5-20 aryl-C 1-7 alkyl, C 3-20 heterocyclyl, or C 1-7 alkyl, and is optionally substituted; R alk is a C 2-10 alkylene group, and is optionally substituted; and Q is independently —H or an organic group having from 1 to 30 atoms selected from carbon, nitrogen, oxygen, sulfur, phosphorus, fluorine, chlorine, bromine, and iodine (e.g., an oxy-type group, an amine-type group, etc.); and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit osteoclast survival, formation, and/or activity, and to inhibit conditions mediated by osteoclasts and/or characterised by bone resorption, in the treatment of bone disorders such as osteoporosis, rheumatoid arthritis, cancer associated bone disease, Paget's disease, and the like; and/or in the treatment of conditions associated with inflammation or activation of the immune system.

  本发明涉及某些芳基烷基磺酰胺及其衍生物，其中，它们抑制破骨细胞的存活、形成和/或活性；和/或抑制骨吸收，更具体地说，是式子的化合物： 其中：Ar1独立地是C5-20芳基（例如，联苯、菲、芴或咔唑基，最好是联苯），并且可以选择性地被取代；RN独立地是-H、酰基、C5-20芳基-C1-7烷基、C3-20杂环基或C1-7烷基，并且可以选择性地被取代；Ralk是C2-10烷基链，可以选择性地被取代；Q独立地是-H或具有1-30个由碳、氮、氧、硫、磷、氟、氯、溴和碘选择的有机基团（例如，氧型基团，胺型基团等）；以及其药学上可接受的盐、溶剂化合物、酰胺、酯、醚、化学保护形式和前药。本发明还涉及包含这样的化合物的制药组合物，以及在体外和体内使用这样的化合物和组合物来抑制破骨细胞的存活、形成和/或活性，并抑制由破骨细胞介导和/或通过骨吸收表征的骨疾病的治疗，例如骨质疏松症、类风湿性关节炎、与癌症相关的骨疾病、帕吉特病等；和/或用于治疗与炎症或免疫系统激活有关的疾病。
• Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions
  申请人：Ralston Hamilton Stuart

  公开号：US20070027112A1

  公开（公告）日：2007-02-01

  The present invention pertains to certain ketones and reduced ketones and derivatives thereof which, inter alia, inhibit osteoclast survival, formation, and/or activity; and/or inhibit bone resorption, and more particularly to compounds of the formulae: (1) (2) wherein: Ar 1 is independently a biphenyl, phenanthryl, fluorenyl, or carbazolyl, and is optionally substituted; R alk is independently a C 2-10 alkylene group, and is optionally substituted; —OR O , if present, is independently —OH or —OR K ; —OR K , if present, is independently selected from: —O—R K1 ; —O—C(═O)R K2 ; —O—C(═O)OR K3 ; —O—S(═O)2OR K4 ; Q is independently —OH or —OR OT ; wherein: —OR OT , if present, is independently selected from: —O—R E1 ; —O—C(═O)—R E2 ; —O—C(═O)—O—R E3 ; —O—C(═O)—O—SO 3 R E4 ; —O—C(═O)—O—(CH 2 ) n —COOR E5 ; —O—C(═O)—(CH 2 ) n —NR N1 R N2 ; —O—C(═O)—(CH 2 ) n —NH—C(═O)R E6 ; —O—C(═O)—(CH 2 ) n —C(═O)—NR N3 R N4 ; —O—P(═O)(OR E7 )(OR E8 ); —O—R PA ; R PA , if present, is an organic group which incorporates a phosphonic acid group; with the proviso A that if —OR OT is —O—R E1 , then R E1 is not a phenyl group substituted with a sulfonyl group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, or prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit osteoclast survival, formation, and/or activity, and to inhibit conditions mediated by osteoclasts and/or characterised by bone resorption, in the treatment of bone disorders such as osteoporosis, rheumatoid arthritis, cancer associated bone disease, Paget's disease, aseptic loosening of prosthetic implants, and the like; and/or in the treatment of conditions associated with inflammation or activation of the immune system.

  本发明涉及某些酮和还原酮及其衍生物，其中包括抑制破骨细胞的存活、形成和/或活性；和/或抑制骨吸收的化合物，更具体地说，是以下式子的化合物：（1）（2） 其中：Ar1独立地是联苯基，菲基，芴基或咔唑基，且可以被取代；Ralk独立地是C2-10烷基，且可以被取代；-ORO，如果存在，则独立地是-OH或-ORK；-ORK，如果存在，则独立地选自：-O-RK1；-O-C（═O）-RK2；-O-C（═O）-ORK3；-O-S（═O）2ORK4；Q独立地是-OH或-OROT；其中：-OROT，如果存在，则独立地选自：-O-RE1；-O-C（═O）-RE2；-O-C（═O）-O-RE3；-O-C（═O）-O-SO3RE4；-O-C（═O）-O-（CH2）n-COORE5；-O-C（═O）-（CH2）n-NRN1RN2；-O-C（═O）-（CH2）n-NH-C（═O）RE6；-O-C（═O）-（CH2）n-C（═O）-NRN3RN4；-O-P（═O）（ORE7）（ORE8）；-O-RPA；如果存在RPA，则是包含膦酸基的有机基团；但前提是如果-OROT是-O-RE1，则RE1不是取代有磺酰基的苯基；以及其药学上可接受的盐、溶剂化合物、酰胺、酯、醚、化学保护形式或前药。本发明还涉及包含这种化合物的制药组合物，以及这种化合物和组合物的使用，无论是在体内还是体外，以抑制破骨细胞的存活、形成和/或活性，并抑制由破骨细胞介导和/或特征为骨吸收的疾病，如骨质疏松症、类风湿性关节炎、癌症相关骨病、帕吉特病、假体松动等；和/或用于治疗与炎症或免疫系统激活相关的疾病。